Skip to main content
. 2023 Jul 21;9(29):eadi4862. doi: 10.1126/sciadv.adi4862

Table 1. Overview of the reports from clinical NR trials included in this review.

First author Year published Group treated Treatment group size Placebo group size Daily NR dose (mg) Duration Reference in review
Trammell 2016 Healthy 12 0 100, 300, 1000 24 hours (24)
Airhart 2017 Healthy 8 0 2000 8 days (25)
Dellinger 2017 Elderly 40 40 250, 500 60 days (40)
Dollerup 2018 Obese, insulin resistant 20 20 2000 12 weeks (4)
Martens 2018 Elderly 24 24 1000 6 weeks (37)
Conze 2019 Healthy 32–34 34 100, 300, 1000 8 weeks (32)
Dollerup 2019 Obese, insulin resistant 20 20 2000 12 weeks (5)
Elhassan 2019 Elderly 12 12 1000 21 days (33)
de la Rubia 2019 Amyotrophic lateral sclerosis 10–14 10–13 1000* 4 months (43)
Zhou 2020 Heart failure 4 0 2000 9 days (26)
Dollerup 2020 Obese, insulin resistant 20 20 2000 12 weeks (6)
Remie 2020 Obese 13 13 1000 6 weeks (34)
Dolopikou 2020 Young/elderly 12 12 500 2 hours (36)
Simic 2020 Acute kidney injury 3–5 0–2 250, 500, 1000, 2000 2 days (42)
Veenhuis 2021 Ataxia telangiectasia 24 0 25/kg (max 900) 4 months (27)
Stocks 2021 Healthy 8 8 1000 7 days (35)
Nascimento 2021 Obese 8 8 1000 6 weeks (39)
Wang 2022 Heart failure 20 10 2000 12 weeks (29)
Brakedal 2022 Parkinson’s disease 15 15 1000 30 days (30)
Wu 2022 Healthy 12 9 1000 7 days (31)
Vreones 2022 Elderly 24 24 1000 6 weeks (38)
Dellinger 2022 Nonalcholic fatty liver disease 24–36 27–31 250, 500 6 months (41)
Jensen 2022 Elderly 16 15 1000 44 days (8)
Lapatto 2023 Obese 3–16 0 1000 5 months (28)
Peluso 2023 Obese, insulin resistant 20 20 2000 12 weeks (7)

*Not formally disclosed.